Cannabinoids and sepsis

[1]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[2]  W. Graier,et al.  The GPR55 agonist lysophosphatidylinositol acts as an intracellular messenger and bidirectionally modulates Ca2+-activated large-conductance K+ channels in endothelial cells , 2010, Pflügers Archiv - European Journal of Physiology.

[3]  M. Nagarkatti,et al.  Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. , 2010, Immunobiology.

[4]  A. Irving,et al.  GPR55 ligands promote receptor coupling to multiple signalling pathways , 2010, British journal of pharmacology.

[5]  M. Abood,et al.  Pharmacological characterization of GPR55, a putative cannabinoid receptor. , 2010, Pharmacology & therapeutics.

[6]  A. Yamashita,et al.  Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. , 2010, Journal of biochemistry.

[7]  E. Hahn,et al.  Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis. , 2010, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[8]  L. Hunyady,et al.  Signal transduction of the CB1 cannabinoid receptor. , 2010, Journal of molecular endocrinology.

[9]  A. Hohmann,et al.  The endocannabinoid system and pain. , 2009, CNS & neurological disorders drug targets.

[10]  D. Deutsch,et al.  Lipid Droplets Are Novel Sites of N-Acylethanolamine Inactivation by Fatty Acid Amide Hydrolase-2* , 2009, The Journal of Biological Chemistry.

[11]  M. Nagarkatti,et al.  Endocannabinoids and immune regulation. , 2009, Pharmacological research.

[12]  J. Dattilo,et al.  The Cannabinoid Receptor 2 Is Critical for the Host Response to Sepsis1 , 2009, The Journal of Immunology.

[13]  P. Brubaker,et al.  GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell , 2009, Diabetes.

[14]  A. Irving,et al.  The GPR55 ligand L‐α‐lysophosphatidylinositol promotes RhoA‐dependent Ca2+ signaling and NFAT activation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  N. Kaminski,et al.  Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Δ9‐tetrahydrocannabinol , 2008, Journal of leukocyte biology.

[16]  D. Barrett,et al.  ‘Entourage’ effects of N‐palmitoylethanolamide and N‐oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors , 2008, British journal of pharmacology.

[17]  S. Simon,et al.  TRPV1: on the road to pain relief. , 2008, Current molecular pharmacology.

[18]  Yoichi Kase,et al.  Removal of 2‐Arachidonylglycerol by Direct Hemoperfusion Therapy With Polymyxin B Immobilized Fibers Benefits Patients With Septic Shock , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[19]  I. Chessell,et al.  The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain , 2008, PAIN.

[20]  N. Kaminski,et al.  The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). , 2008, Biochemical pharmacology.

[21]  K. Mackie,et al.  Cannabinoid Receptors: Where They are and What They do , 2008, Journal of neuroendocrinology.

[22]  N. Kaminski,et al.  Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Δ9‐tetrahydrocannabinol , 2008, Journal of leukocyte biology.

[23]  C. Reynet,et al.  GPR119, a novel G protein‐coupled receptor target for the treatment of type 2 diabetes and obesity , 2008, British journal of pharmacology.

[24]  K. Mackie,et al.  GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current , 2008, Proceedings of the National Academy of Sciences.

[25]  F. Kunimoto,et al.  Effects of the cannabinoid antagonist AM281 on systemic hemodynamics and mortality rate in streptozotocin‐induced diabetic rats with endotoxic shock: comparison between non‐diabetic and diabetic rats , 2008, Acta anaesthesiologica Scandinavica.

[26]  D. McHugh,et al.  Inhibition of Human Neutrophil Chemotaxis by Endogenous Cannabinoids and Phytocannabinoids: Evidence for a Site Distinct from CB1 and CB2 , 2008, Molecular Pharmacology.

[27]  R. Pertwee.  GPR55: a new member of the cannabinoid receptor clan? , 2007, British journal of pharmacology.

[28]  S. Hjorth,et al.  The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.

[29]  A. Brown.  Novel cannabinoid receptors , 2007, British journal of pharmacology.

[30]  Didier Bagnol,et al.  A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. , 2007, Endocrinology.

[31]  B. Basavarajappa.  Critical enzymes involved in endocannabinoid metabolism. , 2007, Protein and peptide letters.

[32]  Masahiro Tanaka,et al.  The mRNA expression of fatty acid amide hydrolase in human whole blood correlates with sepsis , 2007, Journal of endotoxin research.

[33]  T. Mikkelsen,et al.  A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals* , 2006, Journal of Biological Chemistry.

[34]  C. Sprung,et al.  Sepsis in European intensive care units: Results of the SOAP study* , 2006, Critical care medicine.

[35]  I. Nagy,et al.  Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons , 2005, Neuroscience.

[36]  F. Kunimoto,et al.  Cannabinoid antagonist AM 281 reduces mortality rate and neurologic dysfunction after cecal ligation and puncture in rats , 2005, Critical care medicine.

[37]  T. Klein.  Cannabinoid-based drugs as anti-inflammatory therapeutics , 2005, Nature Reviews Immunology.

[38]  L. Urbán,et al.  The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. , 2004, European journal of pharmacology.

[39]  Alan Saghatelian,et al.  Functional disassociation of the central and peripheral fatty acid amide signaling systems. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Murakami,et al.  Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. , 2004, The Biochemical journal.

[41]  F. Rossi,et al.  Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia‐reperfusion injury: involvement of cytokine/chemokines and PMN , 2004, Journal of leukocyte biology.

[42]  Xiang-Qun Xie,et al.  3D structural model of the G‐protein‐coupled cannabinoid CB2 receptor , 2003, Proteins.

[43]  Raymond C Stevens,et al.  Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling , 2002, Science.

[44]  M. Roth,et al.  Respiratory and Immunologic Consequences of Marijuana Smoking , 2002, Journal of clinical pharmacology.

[45]  M. Nagarkatti,et al.  Δ9-Tetrahydrocannabinol-Induced Apoptosis in the Thymus and Spleen as a Mechanism of Immunosuppression in Vitro and in Vivo , 2002, Journal of Pharmacology and Experimental Therapeutics.

[46]  K. Mackie,et al.  Cloning and molecular characterization of the rat CB2 cannabinoid receptor. , 2002, Biochimica et biophysica acta.

[47]  B. Löwenberg,et al.  Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. , 2002, Blood.

[48]  M. Glass,et al.  CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[49]  D. Parolaro,et al.  Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat , 2002, British journal of pharmacology.

[50]  L. Petrocellis,et al.  Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. , 2001, Archives of biochemistry and biophysics.

[51]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[52]  C. Newton,et al.  Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. , 2001, European journal of pharmacology.

[53]  Derek C. Angus,et al.  Epidemiology of sepsis: An update , 2001, Critical care medicine.

[54]  C. Newton,et al.  The Cannabinoid System and Cytokine Network , 2000 .

[55]  G. Denhardt,et al.  Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. , 2000, The Journal of pharmacology and experimental therapeutics.

[56]  M. Herkenham,et al.  Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  P. Casellas,et al.  Cannabinoid receptor CB1 activates the Na+/H+ exchanger NHE‐1 isoform via Gi‐mediated mitogen activated protein kinase signaling transduction pathways , 1999, FEBS letters.

[58]  H. Heng,et al.  Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. , 1999, Brain research. Molecular brain research.

[59]  S. Galiègue,et al.  Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. , 1998, Blood.

[60]  Wayne Hall,et al.  Adverse effects of cannabis , 1998, The Lancet.

[61]  S. Burstein,et al.  Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. , 1998, Biochimica et biophysica acta.

[62]  G. Kunos,et al.  Platelet‐ and macrophage‐derived endogenous cannabinoids are involved in endotoxin‐induced hypotension , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  T. Klein,et al.  Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. , 1998, The Journal of pharmacology and experimental therapeutics.

[64]  D. Lambert,et al.  Pharmacology and potential therapeutic uses of cannabis. , 1998, British journal of anaesthesia.

[65]  L. Petrocellis,et al.  The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. , 1998, The Biochemical journal.

[66]  E. Ellis,et al.  Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock , 1997, Nature.

[67]  D. Bates,et al.  Epidemiology of sepsis syndrome in 8 academic medical centers. , 1997, JAMA.

[68]  V. Lagente,et al.  Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. , 1997, European journal of pharmacology.

[69]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[70]  V. Di Marzo,et al.  Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. , 1996, The Biochemical journal.

[71]  P. Ferrara,et al.  Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. , 1996, Biochimica et biophysica acta.

[72]  P. Casellas,et al.  Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. , 1996, European journal of biochemistry.

[73]  E. Shohami,et al.  A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. , 1996, The Journal of infectious diseases.

[74]  Y. Daaka,et al.  Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. , 1996, The Journal of pharmacology and experimental therapeutics.

[75]  P. Casellas,et al.  Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. , 1995, The Biochemical journal.

[76]  P. Casellas,et al.  Cannabinoids enhance human B‐cell growth at low nanomolar concentrations , 1995, FEBS letters.

[77]  S. Galiègue,et al.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.

[78]  Y. Daaka,et al.  Δ9-Tetrahydrocannabinol, Cytokines, and Immunity to Legionella pneumophila , 1995, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[79]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[80]  B. Martin,et al.  Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. , 1995, European journal of pharmacology.

[81]  A. Buriani,et al.  Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[82]  N. Kaminski,et al.  Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. , 1994, Biochemical pharmacology.

[83]  F. Blanco,et al.  Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis , 1994, Journal of Neuroimmunology.

[84]  C. Newton,et al.  Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection , 1994, Infection and immunity.

[85]  C. Newton,et al.  Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. , 1993, The Journal of pharmacology and experimental therapeutics.

[86]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[87]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[88]  S. Smith,et al.  Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus , 1979, Infection and immunity.

[89]  D. Baker,et al.  In silico patent searching reveals a new cannabinoid receptor. , 2006, Trends in pharmacological sciences.

[90]  Y. Masuda,et al.  Anandamide absorption by direct hemoperfusion with polymixin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis , 2005, Journal of Anesthesia.

[91]  R. Pertwee,et al.  Pharmacological actions of cannabinoids. , 2005, Handbook of experimental pharmacology.

[92]  S. Burstein,et al.  Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. , 1998, Arthritis and rheumatism.

[93]  L. Hollister.  Marijuana and immunity. , 1992, Journal of psychoactive drugs.